Royalty Pharma (RPRX) EPS (Weighted Average and Diluted) Growth (1y) (2021 - 2026)
Royalty Pharma (RPRX) EPS (Weighted Average and Diluted) Growth (1y) (2021 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
EPS (Weighted Avg. Diluted) Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
251.11% |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
-13.31% |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
102.51% |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
-79.34% |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
-103.05% |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
61.45% |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Royalty Pharma |
23.13 Bn |
25.57 Bn |
- |
21.82% |
| Date | Value |
|---|
| Mar 31, 2026 |
21.82% |
| Dec 31, 2025 |
6.38% |
| Sep 30, 2025 |
-44.63% |
| Jun 30, 2025 |
-69.57% |
| Mar 31, 2025 |
5,400.00% |
| Dec 31, 2024 |
-57.27% |
| Sep 30, 2024 |
656.25% |
| Jun 30, 2024 |
-54.00% |
| Mar 31, 2024 |
-98.68% |
| Dec 31, 2023 |
205.77% |
| Sep 30, 2023 |
-50.00% |
| Jun 30, 2023 |
-28.57% |
| Mar 31, 2023 |
533.33% |
| Dec 31, 2022 |
-903.77% |
| Sep 30, 2022 |
33.33% |
| Jun 30, 2022 |
-35.19% |
| Mar 31, 2022 |
-33.33% |
| Dec 31, 2021 |
-70.59% |
| Sep 30, 2021 |
-69.62% |
| Jun 30, 2021 |
1,100.00% |
